BiotechTube

Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]

Pre-clinicalUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatitis C in Substance Users

Conditions

Hepatitis C in Substance Users

Trial Timeline

Nov 15, 2022 → May 15, 2024

NCT ID
NCT05503979

About Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]

Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] is a pre-clinical stage product being developed by Gilead Sciences for Hepatitis C in Substance Users. The current trial status is unknown. This product is registered under clinical trial identifier NCT05503979. Target conditions include Hepatitis C in Substance Users.

What happened to similar drugs?

20 of 20 similar drugs in Hepatitis C in Substance Users were approved

Approved (20) Terminated (8) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Pegylated Interferon + RibavirinAstellas PharmaApproved
✅Glecaprevir-pibrentasvirAbbVieApproved
✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved
✅PTV/r/OBV/DSVAbbVieApproved
✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved
✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved

Hype Score Breakdown

Clinical
3
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05503979Pre-clinicalUNKNOWN

Competing Products

20 competing products in Hepatitis C in Substance Users

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
43
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
40
SOF + COPEChugai PharmaceuticalPre-clinical
26
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
FK788Astellas PharmaPhase 2
35
MK-2248MerckPhase 1
29
Interferon alfacon-1Astellas PharmaPhase 3
40
Pegylated Interferon + RibavirinAstellas PharmaApproved
35
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir + MethadoneShionogiPhase 1
29
Clevudine + AdefovirEisaiPhase 3
40